Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Neurogene Inc.

Neurogene is focused on developing genetic medicines for patients affected by neurological diseases, self-described as turning the promise of gene therapy into reality.

Neurogene

Neurogene Inc. | 14,081 followers on LinkedIn. Reimagining the future for rare neurological diseases | Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies.

Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders.

Cara Mayfield

Anandita Seth

Associate Director - Manufacturing Science and Technology | Advancing Gene Therapy for Complex Genetic Diseases

Mihaela Trumbo, MS

Senior Director Clinical Operations at Neurogene Inc.

Anjanette Enmyeche

Interim clinical data from our Phase 1/2 trial of NGN-401 for Rett syndrome will be featured during a late-breaker session at the 2024 Child Neurology Society Annual Meeting. Join our live webcast on November 11 at 4:30 p.m. ET for a review of the data! For more details, visit: https://bit.ly/3YtRgXk #CNSAM #GeneTherapy

Attending Cell & Gene’s 2024 Meeting on the Mesa? Don’t miss our Founder and Chief Executive Officer, Dr. Rachel McMinn, participate in a Science Slam focused on neurological disease. Alliance for Regenerative Medicine #MeetingontheMesa #cellandgene #CGMesa24 #GeneTherapy

Tune in today at 2:30 p.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the Cantor Global Healthcare Conference. A link to the webcast is available here: https://bit.ly/4g3hTsT #CantorHCC

Tune in today at 11:00 a.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference. A link to the webcast is available here: https://bit.ly/4dWYFDE #HCWainwrightGlobal

Today, we reported second quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: https://bit.ly/3YELJ0O

We are excited to announce that the FDA has granted Regenerative Medicine Advanced Therapy #RMAT designation to NGN-401 for #RettSyndrome . RMAT designation is based on preliminary clinical evidence that a drug has the potential to address unmet medical needs. We look forward to continued collaboration with the FDA as we continue advancing our mission to bring life-changing medicines to those who are impacted by rare neurological diseases. #RMAT #Genetherapy #RettSyndrome To learn more, read today’s press release: https://bit.ly/3T2HyZ9

🥼 Neurogene Inc is on a mission: to improve the lives of patients and families devastated by rare neurological diseases. 🧬 The medicine Neurogene Inc. is creating has the potential to fundamentally change the way these disorders are treated. 🔔 We are so proud to be your partner $NGNE! Thrilled to welcome you to ring the Nasdaq Opening Bell! #NasdaqListed

Nasdaq

Thank you Nasdaq for hosting us for an amazing morning ringing today’s opening bell! Watch the ceremony here: https://bit.ly/4dufaXu #NasdaqBell #NasdaqListed $NGNE #Genetherapy #Biotech

On Tuesday, July 9, management will participate in the BMO 2024 Genetic Medicines Summit. To learn more, read our full press release here: https://bit.ly/3L68OBx

Today, we joined the Russell 3000® Index as part of the Russell indexes annual reconstitution. We are proud of all that we have accomplished that has enabled our addition to this industry benchmarking index. #RussellRecon Read our full press release here: https://bit.ly/4eMgh69

	Dec '21	Dec '22	Dec '23
net income	-50.52M -	-55.19M 9.25%	-36.32M 34.20%
depreciation and amortization	947K -	3.20M 237.91%	3.30M 3.03%
deferred income tax			-105K -
stock based compensation	896K -	1.25M 39.73%	1.42M 13.26%
change in working capital	1.59M -	-2.69M 268.97%	-4.02M 49.28%
accounts receivables
inventory
accounts payables	2.98M -	-3.61M 220.96%	667K 118.49%
other working capital	-1.39M -	912K 165.75%	-4.69M 614.25%
other non cash items	679K -	608K 10.46%	-15.69M 2,680.92%
net cash provided by operating activities	-46.40M -	-52.82M 13.84%	-51.42M 2.65%
investments in property plant and equipment	-18.37M -	-2.23M 87.86%	-321K 85.61%
acquisitions net
purchases of investments
sales maturities of investments			5M -
other investing activites			20.96M -
net cash used for investing activites	-18.37M -	-2.23M 87.86%	25.64M 1,249.64%
debt repayment	-51K -	-1K 98.04%	-29K 2,800%
common stock issued	783K -	66.53M 8,397.06%	92.34M 38.79%
common stock repurchased
dividends paid
other financing activites			92.34M -
net cash used provided by financing activities	51.06M -	66.53M 30.29%	92.48M 39.01%
effect of forex changes on cash
net change in cash	-13.71M -	11.48M 183.74%	66.70M 481.14%
cash at beginning of period	84.25M -	70.54M 16.27%	82.02M 16.27%
cash at end of period	70.54M -	82.02M 16.27%	148.72M 81.32%
operating cash flow	-46.40M -	-52.82M 13.84%	-51.42M 2.65%
capital expenditure	-18.37M -	-2.23M 87.86%	-321K 85.61%
free cash flow	-64.77M -	-55.05M 15.00%	-51.74M 6.01%

NGNE

COM:NEUROGENE

Neurogene

Last Close

15.59

22/11 21:00

Market Cap

500.52M

Beta: -

Volume Today

1.06M

Avg: -

Preview